文传商讯
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonis
2024-02-19 18:41:20
Galderma Launches ‘NEXT’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics
2024-02-19 18:41:20



